已收盘 12-19 16:00:00 美东时间
-1.480
-100.00%
Nutriband Inc. announced the issuance of a U.S. patent for its AVERSA™ abuse deterrent transdermal technology, expanding intellectual property coverage in the U.S. The technology aims to prevent drug abuse, diversion, and misuse through transdermal patches. Nutriband's lead product, Aversa™ Fentanyl, has the potential to become the first abuse deterrent pain patch, with estimated annual sales reaching $80 million to $200 million.
06-09 11:30
<p>Nutriband Inc. announces that CEO Gareth Sheridan will present at Noble Capital Markets’ virtual conference on June 5th, 4PM EST. The presentation includes a Q&A session and 1x1 investor meetings. A webcast will be available on the company’s website and Channelchek for 90 days.</p>
06-03 12:00